ASCO Annual Meeting Coverage
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology
Roche used its ASCO investor briefing to highlight its digital and personalized healthcare strategy, including examples of how it’s facilitating R&D and reimbursement – and how that should position it to be an oncology leader in the future.
As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche
The US FDA has granted priority review for Pfizer's talazoparib, which would be the fourth PARP inhibitor on the market, though only the second for breast cancer behind Lynparza. Pfizer has a long-term eye on a combination of talazoparib with its PD-L1 inhibitor Bavencio, Oncology CMO Rothenberg told Scrip at ASCO.
Latest From ASCO
AstraZeneca Looks To Deliver On Its Promises In Oncology
Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO.
CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie
Pfizer's Ibrance has a strong lead in the CDK4/6 space, but Novartis' Kisqali and Lilly's Verzenio are looking to carve out their own niches, expand the category and move into earlier treatment settings. Another scramble is on as well, to answer the question: what comes next?
TMB Biomarker Is A Winding Path Rather Than Straight Road
The tumor mutational burden biomarker had a much higher profile at this year's ASCO meeting, promising to help target treatment to individuals, though practical barriers remain and testing still is not ready for prime time yet.
Specialists Rethink Lung Cancer Treatment Plans, With Eye On IO Biomarkers
Plenary speaker at this year's ASCO meeting, Leena Gandhi, envisioned a future where individual patients receive a precisely defined immunotherapy regimen.
Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program
Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.
Novartis' New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands
Liz Barrett joined Novartis in February after leading Pfizer's oncology unit, taking over leadership of the business at a time of transition and tasked with building new blockbusters as old reliable work engines mature. She talked to Scrip about her plans for Novartis Oncology at ASCO.
Will Pierre Fabre and Array Have Best-In-Class MEK/BRAF Inhibitor?
Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.
Phase III Data ENLIVEN Pexidartinib’s Prospects But Liver Tox An Issue?
Phase III results for Daiichi Sankyo’s pexidartinib presented at ASCO provide new hope in a rare tumor type with no approved therapies, but hepatic toxicity also emerged as a safety issue in the study.
Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO
With Merck's Keytruda on top of the world and setting the standard for PD-1/L1 lung cancer data, Roche and Bristol defended the programs for their competing Tecentriq and Opdivo during ASCO investor events.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.